Skip to main content
Lupin Ltd logo

Lupin Ltd — Investor Relations & Filings

Ticker · LUPIN ISIN · INE326A01037 LEI · 335800HHXTESDEE2FC65 BSE.NS Manufacturing
Open in API
Filings indexed 3,182 across all filing types
Latest filing 2021-11-08 Regulatory Filings
Country IN India
Listing BSE.NS LUPIN

About Lupin Ltd

https://www.lupin.com/

Lupin Ltd is a global pharmaceutical organization specializing in the development, manufacturing, and marketing of a comprehensive range of generic and branded formulations, biotechnology products, and active pharmaceutical ingredients. The company holds a significant market position in therapeutic segments such as cardiovascular, diabetology, asthma, pediatrics, gastrointestinal, anti-infectives, and non-steroidal anti-inflammatory drugs. It is notably recognized for its leadership in the anti-tuberculosis medication sector. With a strong emphasis on research and development, Lupin focuses on complex generics, specialty medicines, and biosimilars. The company operates advanced manufacturing facilities and maintains a substantial commercial presence across major global markets, including North America, Europe, and the Asia-Pacific region, delivering affordable and high-quality healthcare solutions.

Recent filings

Filing Released Lang Actions
Press Release
Regulatory Filings Classification · 90% confidence The document contains only placeholders for images and no textual content or financial data. It is extremely short (194 characters) and does not contain any report, announcement, or detailed information. Given the lack of content, it cannot be classified as a substantive report or announcement. It fits best as a Regulatory Filing (RNS) as a fallback category for miscellaneous filings without meaningful content.
2021-11-08 English
Lupin's Namuscla® (mexiletine) is recommended by NICE for treatment of symptomatic myotonia in adults with non-dystrophic myotonic disorders.
Regulatory Filings Classification · 95% confidence The document is a press release dated November 4, 2021, from Lupin Limited, announcing that the National Institute for Health and Care Excellence (NICE) has issued a Final Appraisal Determination recommending the use of Lupin's drug Namuscla (mexiletine) for treating symptoms of myotonia in adults with non-dystrophic myotonic disorders. The text includes detailed information about the drug, clinical studies, and company background. It is addressed to stock exchanges as a disclosure pursuant to SEBI regulations. The document is not a financial report, earnings release, or regulatory filing in the traditional sense but rather a corporate announcement about a product approval and recommendation. It does not contain financial statements or management discussion of financial results. It is not a report publication announcement since it is a substantive press release with detailed information. The document fits best under Regulatory Filings (RNS) as it is a regulatory disclosure about a material event (drug approval and recommendation) that affects the company but is not a financial report or other specific filing type.
2021-11-04 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release dated November 4, 2021, from Lupin Limited, addressed to stock exchanges in India, disclosing a regulatory update pursuant to SEBI regulations. It announces that the UK's National Institute for Health and Care Excellence (NICE) has issued a Final Appraisal Determination recommending Lupin's drug Namuscla (mexiletine) for treatment of myotonia in adults with non-dystrophic myotonic disorders. The document includes detailed product information, clinical particulars, and references to studies supporting the drug's efficacy and safety. There are no financial statements, earnings data, or management discussion of financial results. The document is primarily a regulatory disclosure and press release about a product approval and recommendation, not a financial report or management report. It is not a report publication announcement since it contains substantive information rather than just announcing a report's release. It is not a call transcript, audit report, or any other financial filing. The closest fitting category is Regulatory Filings (RNS) as it is a regulatory disclosure pursuant to SEBI regulations about a material event (drug approval and recommendation) that affects the company but does not fit other specific categories.
2021-11-04 English
Press Release
Regulatory Filings
2021-11-03 English
Lupin Launches Authorized Generic Version of Antara® in the United States
Regulatory Filings Classification · 95% confidence The document is a press release announcing the launch of an authorized generic version of a pharmaceutical product by Lupin Limited. It is addressed to stock exchanges as a disclosure pursuant to Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. The content is a corporate announcement about a product launch, not a financial report, earnings release, or regulatory filing of financial data. It does not contain financial statements or detailed financial analysis. The document length is 3181 characters, which is relatively short and typical for a press release or regulatory disclosure. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other specific categories.
2021-11-03 English
News Verification
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the National Stock Exchange of India referencing a surveillance letter. It discusses ongoing business activities such as marketing alliances and acquisitions but does not provide detailed financial data or results. The letter states that the company will inform the stock exchanges when any marketing alliances are finalized and mentions that these will not materially impact revenues. The document is short (1087 characters) and serves as a regulatory communication or update rather than a full report or announcement of financial results. It does not fit into categories like Annual Report, Earnings Release, or Capital/Financing Update. It is best classified as a Regulatory Filing (RNS) because it is a compliance-related communication responding to a regulatory query without substantive financial data or report content.
2021-11-02 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.